Gain Therapeutics
GANX
48 hedge funds and large institutions have $25.9M invested in Gain Therapeutics in 2025 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 15 increasing their positions, 3 reducing their positions, and 10 closing their positions.
400% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 3
237% more capital invested
Capital invested by funds: $7.7M → $25.9M (+$18.2M)
157% more call options, than puts
Call options by funds: $375K | Put options by funds: $146K
110% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 10
26% more funds holding
Funds holding: 38 → 48 (+10)
8.87% more ownership
Funds ownership: 12.08% → 20.95% (+8.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$3.97M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.61M |
| 3 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$667K |
| 4 |
Jane Street
New York
|
+$453K |
| 5 |
CAM
Cresset Asset Management
Chicago,
Illinois
|
+$427K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$997K |
| 2 |
Renaissance Technologies
New York
|
-$290K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$159K |
| 4 |
VF
Virtu Financial
New York
|
-$96K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$95.9K |
GANX Hedge Fund Activity: Q4 2025 in Review
48 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Gain Therapeutics (GANX) for Q4 2025, worth a combined $25.9M — up 237% from $7.7M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new GANX positions and 10 closed out — a net gain of 11 holders — while 15 added to existing stakes and 3 trimmed.
The largest buyer was Marshall Wace, adding an estimated $3.97M. The largest seller was Citadel Advisors, exiting entirely with an estimated $997K sold.
- 48 institutional investors held Gain Therapeutics (GANX) as of Q4 2025, up from 38 in Q3 2025.
- Funds reported $25.9M of Gain Therapeutics stock for Q4 2025, up 237% quarter-over-quarter.
- 21 funds opened new Gain Therapeutics positions in Q4 2025 and 10 closed out, a net change of +11 holders.
- The largest Gain Therapeutics buyer in Q4 2025 was Marshall Wace, an estimated $3.97M added.
- The largest Gain Therapeutics seller in Q4 2025 was Citadel Advisors, an estimated $997K sold.
Based on aggregated 13F filings for Q4 2025.